1 in 5 Patients Report Skin Toxicity With Melanoma Rx ...Middle East

Medscape - News
1 in 5 Patients Report Skin Toxicity With Melanoma Rx
In patients with advanced melanoma, nivolumab/relatlimab combination therapy shows a cutaneous irAEs prevalence of 21.5%, with rash and maculopapular eruption being most common. Medscape Medical News

Read More Details
Finally We wish PressBee provided you with enough information of ( 1 in 5 Patients Report Skin Toxicity With Melanoma Rx )

Also on site :